Graft-Versus-Host Disease
74
10
14
40
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
20 trials with published results (27%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
10.8%
8 terminated out of 74 trials
83.3%
-3.2% vs benchmark
5%
4 trials in Phase 3/4
50%
20 of 40 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 40 completed trials
Clinical Trials (74)
Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Pomalidomide for Chronic Graft-versus-Host Disease
Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis
A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
Measurements of Resting Energy Expenditure in Patients With or at Risk of Developing Graft Versus Host Disease
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)
Safety and Efficacy of Fecal Microbiota Transplantation
Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT
Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function